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Helicobacterpylon: The Middle East Scenario
Ben H. Novis, Gila Gabay and Timna Naftali
Gastroenterology Unit, MeirHospital, Kfar Saba, Israel
A review of Helicobacter pylori in the Middle East is presented. Prevalence
studies have been performed in asymptomatic population groups fromAlgeria,
Israel, Saudi Arabia and Turkey. These showed that the prevalence ofH. pylori
is similar to that of the developing countries of the world with a high level of
infection in childhood (40 to 70 percent), which increases with age to 85 to 90
percent. Israel, however, has a low prevalence in children (10 percent), but there
is a rapid rise in the second decade oflife to 39 percent, reaching 79 percent in
those over 60 years old. The prevalence rates were higher in those living in com-
munal settlements (72 percent) than in urban dwellers (65 percent). The infec-
tion rates were higherin persons ofMediterranean andAsian origin (89 percent)
compared to those of Western European/North American origin (57 percent).
The prevalence rate ofH. pylori infection in patients undergoing endoscopy for
upper gastrointestinal symptoms has now been reported from many Middle
Eastern countries, including Egypt, Iran, Israel, Oman, SaudiArabia, the United
Arab Emirates andYemen. These studies showed that patients with gastritis and
peptic ulcer disease had similar rates of infection as reported from Europe,
United States and Africa (71 to 92 percent). However, patients with non-ulcer
dyspepsia had higher rates of infection (61 to 89 percent). The H. pylori sce-
nario from the prevalence rates, treatment protocols and responses to treatment
does not differ very much from other developing areas of the world.
INTRODUCTION
The prevalence of Helicobacterpylori infection as shown by large epidemiological
prospective studies in an asymptomatic population [1-10] and its prevalence in various
upper gastrointestinal conditions [11-15] has been reported in numerous countries
throughout the world, including those in the Middle East.
Countries in the world may be divided naturally into two groups-the industrialized
developed countries at ahigh socio-economic level, and those developing countries whose
populations live in poor socio-economic conditions. In a similar fashion, the prevalence of
H. pylori in different countries can generally be divided into two groups [16]. The first
consists ofcountries whose population has a high prevalence ofinfection in children, per-
sisting into adult life and old age, while in the second group, the prevalence in childhood
is low, but rises with age.
Where do the countries ofthe Middle East fit into this spectrum?
H. PYLORI IN THE MIDDLE EAST
The Middle East is a region which is difficult to define precisely. For the purposes of
this study, it includes the countries of the ancient fertile crescent (Figure 1), the Arabian
peninsula and the North African countries bordering the southern shores of the
Mediterranean Sea.
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Figure 1. H.pylori in the Middle East.
Prevalence studies based on asymptomatic randomized studies have been reported in
four countries ofthe Middle East [17-20]. Two studies have been reported from Israel [17,
18]. In 1993, a study in 311 asymptomatic individuals from urban Jerusalem was report-
ed. An enzyme immunoassay was used to determine the presence of anti-H. pylori Ig in
individuals aged between 20 to 70 years undergoing periodic health examinations and ran-
domly selected for each decade ofage. A sero-prevalence of65 percent in the overall pop-
ulation was found; it increased with age from 43 percent in those aged between 20 to 30
years to more than 80 percent in those aged 60 years and older. H.pylori infection was not
associated with gender, marital status or with the country of origin.
In a second study from Israel [18], reported in 1995, 377 asymptomatic randomly
chosen members from a number of rural communal settlements (kibbutzim) with an age
range from six to 90 were tested using an ELISA technique. H. pylori infection was pre-
sent in 72 percent of this population. There was an increase among age groups from 10
percent in those aged 0 to 10; to 39 percent in the teenagers; 60 percent in people in their
30s; 70 percent in the 40 to 60 age group and 85 percent in the over 60-year-olds. There
was no significant difference between males and females or number ofyears of living on
the kibbutz. A significant association was found between H. pylori infection and country
oforigin. The highest prevalence was inpeople ofMediterranean andAsian origin, 89 per-
cent, and those of East European origin, 80 percent. People born in Israel had a 66 per-
cent prevalence ofinfection, and those ofNorth and West European origin had the lowest
prevalence of57 percent. This association between H.pylori infection and country ofori-
gin remained true even after adjusting for age. The relatively high prevalence rate in the
kibbutz population might be explained by the communal lifestyle, reminiscent of a very
large family.
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Figure 2. H. pylori prevalence.
In Figure 2 and Table 1, the prevalence of H. pylori infection in the four Middle
Eastern countries in which studies have been reported-Algeria, Israel, Saudi Arabia and
Turkey-is shown and compared with a number of epidemiological studies from Europe
and the USA, which for the purposes of this paper have been combined, as have some
studies from Sub-Saharan Africa andAsia. The two Israeli studies have been combined in
this graph.
In 1990, a study from Saudi Arabia using an ELISA IgG antibodies in 577 persons,
ranging from five to 90 years old, randomly selected from a primary health care facility,
showed a rapid rise in the prevalence ofH. pylori infection from 40 percent in those aged
five to 10 years to over 70 percent in those aged 20 years and 80 percent in those over 50
years.
In 1989, in a seroepidemiology study in four countries, Megraud and Belgouri [1]
examined 277 sera fromAlgerian blooddonors and children attending aprimary care clin-
ic. Children in the first decade of life had a 45 percent prevalence of infection. This rose
Table 1. Epidemiological studies: H.pylori prevalence.
Percent H. pylori positive according to age
Country 0-10 10-20 20-30 30-40 40-50 50-60 >60
Algeria 45 72 82 85 92 85 79
Israel 10 39 42 62 70 76 79
Saudi Arabia 40 50 72 72 72 80 78
Turkey 70 83 77 87 88 90
Europe/USA 7 20 30 40 50 63 67
Africa/Asia 20 40 50 70 80 80 75
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Table 2. H. pylori prevalence in various gastrointestinal conditions.
Country Number Gastritis PU NUD Total
Israel 192 78 86 61 77
Jordan 182 71 84 64 68
UAE* 437 87 95 78 90
Saudi Arabia 201 76 89 89 73
Oman 111 92
Iran 953 86
Egypt 140 93 91 78
Yemen 100 92
Turkey 71 90 90 75 91
Europe 77 89 64 60
USA - 86 90 54 68
Africa 87 89 75 85
*United Arab Emirates
steadily during adult life to reach 92 percent in the fifth decade oflife and dropped slight-
ly to 85 percent in those over 65 years old.
In a Turkish study [20] of 538 subjects serologically tested, a prevalence of 81 per-
cent for all age groups was reported. A tremendously high prevalence of 70 percent was
shown in children up to the age of 10, 83 percent in the 10 to 20 age range, rising to 90
percent in those over 50.
Numerous investigators have studied the prevalence ofH. pylori infection in patients
with peptic ulcer disease, gastritis and duodenitis and non-ulcer dyspepsia [12, 13, 21]. In
Table 2, the results of such studies in nine Middle Eastern countries are shown [22-26].
No significant difference in the prevalence ofH. pylori infection is to be seen in the
figures for gastritis and for peptic ulcer disease in Israel, Jordan [22], the United Arab
Emirates [25], Saudi Arabia [25], Egypt and Turkey, as compared to the figures quoted in
numerous studies from Europe, the U.S. or Sub-Saharan Africa [22].
However, as might be expected, the prevalence ofH. pylori infection in patients with
non-ulcer dyspepsia is higher than that for Europe and the U.S. [21] reflecting the higher
prevalence in most countries of the Middle East.
In a study from Israel, the relevance ofCagA positive H. pylori infection on the clin-
ical course of gastroduodenal pathology was reported [27]. This showed that 24 percent
of 104 consecutive H. pylori infected children tested by an immunoblot technique were
positive for IgG anti-CagA antibodies. This group ofCagA positive patients had a higher
prevalence ofduodenal ulcers (38 percent vs. seven percent) and more active chronic gas-
tritis (82 percent vs. 32 percent).
In another study from Israel, Moshkowitz and his colleagues [28], studying the sea-
sonal variations ofduodenal ulcer disease and its complications. which have been repeat-
edly demonstrated, concluded that the frequency of H. pylori infection in dyspeptic
patients in Israel is significantly increased in the winter months and decreases in the sum-
mer, which is identical to the seasonal variation found in duodenal ulcer disease. The
method they used, which may be questionable, was to compare the monthly variations of
the number of 14C urea breath tests performed in dyspeptic patients referred for investi-
gation, with that ofan unrelated 14C-cholyl-glycine breath test. No seasonal variation was
to be found in the latter, but a significant decrease in the percentage of patients with H.
pylori infection was found in the summer compared to the winter months.
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The same group [29] have also reported on a therapeutic study of omeprazole, clar-
ithromycin and tinidazole in H. pylori infection. They showed that this one-week, low-
dose triple therapy was highly effective as an initial therapy in eradicating H. pylori
infection in 95.7 percent ofcases, as assessed by a 14C-urea breath test, four weeks after
treatment. However, in patients who had previously failed to eradicate H. pylori with a
bismuth, amoxcyillin, metronidazole triple therapy regimen, there was only a 54 percent
eradication rate. This, they do not believe, was due to nitromidazole resistance as 93 per-
cent ofH. pylori isolates were sensitive in an in vitro study. The exact reason forthis dis-
crepancy in eradication results in the two groups thus remains unclear. In a study from
Turkey, Ozden et al. [30] concluded that the recurrence rate ofH. pylori infection during
the first year after eradication was higher (33.3 percent) in populations infected at an
early age.
DISCUSSION
Although the data presented on the prevalence ofH. pylori in the Middle East are not
completely satisfactory, it does suggest again the critical role of socio-economic develop-
ment in determining H. pylori prevalence, particularly in childhood. In general, the preva-
lence in the Middle East seems to place this region in the group with a high level of H.
pylori infection persisting and slowly increasing with age.
Israel would seem to be an exception with a low prevalence rate in childhood, but
with a rapid rise in the second to fourth decade of life, placing it between the developed
and developing countries. This may be explained by the fact that Israel is a country with
a high rate ofimmigration, and, as shown in one study (18), a significant association was
found between the prevalence ofH. pylori and the country oforigin, the rate being high-
est in those ofMediterranean andAsian origin (89 percent) as compared to those ofNorth
American/Western European origin (57 percent).
The higher prevalence rate in the kibbutz population as opposed to the urban popula-
tion in Israel might be explained by the communal lifestyle ofpeople living in close prox-
imity, and perhaps infecting one another.
The finding of a significantly increased H. pylori infection rate in the winter months
in Israel, as compared to the summer months, may be explained by the increased crowd-
ing indoors in the rainy cold winter, providing an increased opportunity for disease trans-
mission.
The prevalence of H. pylori infection in gastroduodenal pathologies in the Middle
East is as can be expected, similar to those of other countries of the world, again con-
forming to the close association of these conditions with H. pylori infection. Bacterial
eradication rates are also probably of a similar rate to other countries, but rates of recur-
rence may be higher.
The Helicobacterpylori scenario in the Middle East, the cradle ofWestern civiliza-
tion, does not differ very much from other developing areas of the world. As this area
develops and the socio-economic situation improves or deteriorates because of uncon-
trolled population growth, it will be of interest to see its effect on the prevalence of H.
pylori infection and the incidence ofupper gastrointestinal pathologies in this area.
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